• Saracatinib (AZD0530): Precision Inhibition in Cancer Biolog

  2026-05-15

  Saracatinib (AZD0530) delivers potent, selective Src/Abl kinase inhibition for robust cancer cell proliferation and migration assays. Its validated workflows, high solubility, and unique cross-applicability in both oncology and synaptic plasticity research set it apart as a foundational tool for advanced experimental design.

• Amitriptyline HCl: Practical Guidance for Lab Research Workf

  2026-05-14

  Amitriptyline HCl supports precise modulation of neurotransmitter receptors in neuropharmacology and mood disorder research. This compound is optimized for CNS-focused assays that require high solubility and validated purity. It is not indicated for long-term solution storage or applications outside the neuropsychiatric context.

• Applied Use-Cases for EZ Cap™ Firefly Luciferase mRNA in Bio

  2026-05-14

  EZ Cap™ Firefly Luciferase mRNA empowers researchers with high-sensitivity bioluminescent reporting, outperforming traditional constructs in translation efficiency and stability. This article details optimized experimental workflows, troubleshooting strategies, and actionable insights inspired by recent advances in mRNA delivery for robust gene regulation and in vivo imaging.

• Nigericin Sodium Salt: Technical Guidance for Ion Transport

  2026-05-13

  Nigericin sodium salt is used to manipulate ion gradients, particularly K+/H+ exchange, across biological membranes in research workflows. It is essential for experiments probing cytoplasmic pH regulation, platelet aggregation modulation, and selective lead ion transport. This product should not be used in diagnostic or medical applications, and suitability must be confirmed for each experimental context.

• FOXO3-Mediated Dual Metabolic Inhibition in Hepatocellular C

  2026-05-13

  This study identifies FOXO3 as a central suppressor of glycolysis and glutaminolysis in hepatocellular carcinoma (HCC) by repressing YAP transcription. Pharmacological activation of FOXO3 disrupts tumor metabolism and growth, presenting a compelling avenue for metabolic-based HCC interventions.

• Therapeutic Targeting of BCL-XL and MCL-1 in Glioblastoma

  2026-05-12

  This study demonstrates that glioblastoma (GBM) cells, particularly stem-like subpopulations, exhibit elevated expression of anti-apoptotic BCL-XL and MCL-1, increasing their susceptibility to BH3-mimetic–induced apoptosis. Sequential inhibition of these proteins induces robust tumor regression in preclinical models, highlighting a promising strategy for overcoming GBM resistance mechanisms.

• PKH26 Red Fluorescent Cell Linker Kit: Protocol and QC Guide

  2026-05-12

  The PKH26 Red Fluorescent Cell Linker Kit enables stable, minimally toxic labeling of cell membrane lipid regions for reliable cell tracing and proliferation detection in both in vitro and in vivo research. It should be used strictly for membrane-focused applications and is not suitable for intracellular or non-membrane labeling. Adhering to protocol and workflow recommendations is essential for reproducibility.

• Biochemical Characterization of GOB-38 β-Lactamase in E. ano

  2026-05-11

  This study elucidates the biochemical properties and substrate specificity of the metallo-β-lactamase GOB-38, newly identified in Elizabethkingia anophelis. The findings reveal GOB-38’s broad hydrolytic activity against multiple β-lactam antibiotics and its potential to mediate resistance transfer, informing both resistance surveillance and inhibitor screening strategies.

• Cefepime (BMY-28142): Applied Models for Antimicrobial Profi

  2026-05-11

  Cefepime (BMY-28142) empowers central nervous system infection research through its broad-spectrum efficacy and blood-brain barrier penetration. This guide details optimized workflows, troubleshooting, and data-driven insights for maximizing reproducibility and translational value with APExBIO’s research-grade material.

• Sodium Picosulfate: Redefining Constipation Research Models

  2026-05-10

  Explore the advanced scientific applications of Sodium Picosulfate in constipation research, including its mechanistic role in gut motility and electrolyte modulation. This article uniquely bridges preclinical protocols with neuroinflammation research for translational insight.

• Erlotinib (NSC 718781): Optimizing EGFR Inhibition in Cancer

  2026-05-09

  Erlotinib (NSC 718781) delivers unparalleled precision for EGFR signaling pathway inhibition in cancer research, enabling reproducible functional studies from cell-based assays to in vivo models. This guide translates recent reference breakthroughs into actionable experimental protocols, troubleshooting, and optimized workflows—empowering researchers to resolve resistance mechanisms and drive next-generation oncology discoveries.

• Nadolol (SQ-11725): Advanced Workflows for Vascular Research

  2026-05-09

  Nadolol (SQ-11725) enables highly reproducible and translational cardiovascular disease models, thanks to its dual role as a non-selective beta-adrenergic blocker and OATP1A2 substrate. This guide delivers stepwise experimental insights, troubleshooting tactics, and comparative advantages for researchers targeting hypertension, angina pectoris, and vascular headache pathways.

• QSHXO Modulates Autophagy and Ferroptosis in MASLD Models

  2026-05-08

  Liu et al. demonstrate that Qushi Huoxue ointment (QSHXO) alleviates metabolic associated steatotic liver disease (MASLD) in mice by concurrently activating autophagy and inhibiting ferroptosis. This mechanistic insight provides a foundation for targeted therapeutic strategies in MASLD and suggests translational potential for interventions modulating the Nrf2 pathway.

• MLN4924: NEDD8-Activating Enzyme Inhibitor for Cancer Biolog

  2026-05-07

  MLN4924 delivers unmatched selectivity and potency as a NEDD8-activating enzyme inhibitor, empowering researchers to unravel neddylation-mediated control of protein degradation and cell cycle progression in cancer models. This article translates cutting-edge findings into practical workflows, troubleshooting strategies, and comparative insights, equipping labs for reproducible and insightful cancer biology research.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-07

  This study presents the discovery of a new series of potent, allosteric pyruvate dehydrogenase kinase 4 (PDK4) inhibitors, with compound 8c demonstrating nanomolar activity, metabolic stability, and efficacy in in vivo models of metabolic and allergic diseases. The findings highlight the therapeutic promise of targeting PDK4 in metabolic syndrome and related disorders.

450 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page